Ozanimod in relapsing forms of multiple sclerosis: a profile of its use

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflicts of interest M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here

Abstract

Ozanimod (Zeposia®), a sphingosine 1-phosphate (S1P) receptor modulator with high selectivity for S1P receptor subtypes 1 and 5 (S1P1 and S1P5), represents another oral disease-modifying therapy option for the treatment of relapsing forms of multiple sclerosis (MS) in adults. In two randomised, double-blind, phase 3 clinical trials, once-daily oral ozanimod 0.92 mg significantly reduced annualised relapse rates and MRI lesion accumulation compared with once-weekly intramuscular interferon β-1a 30 µg. Furthermore, an ongoing open-label extension study provides evidence that the therapeutic effects of ozanimod are sustained in the longer term. Ozanimod is generally well tolerated. The once-daily oral administration provides a convenient dosing regimen, and the high selectivity for S1P1 and S1P5 receptors has the potential to improve safety by reducing potential off-target effects.

© Springer Nature Switzerland AG 2020